Implications of the new nomenclature of steatotic liver disease and definition of metabolic dysfunction-associated steatotic liver disease

被引:24
|
作者
Loomba, Rohit [1 ,2 ,3 ,6 ]
Wong, Vincent Wai-Sun [4 ,5 ]
机构
[1] Univ Calif San Diego, MASLD Res Ctr, Div Gastroenterol & Hepatol, La Jolla, CA USA
[2] Univ Calif San Diego, Div Gastroenterol & Hepatol, La Jolla, CA USA
[3] Univ Calif San Diego, Sch Publ Hlth, La Jolla, CA USA
[4] Chinese Univ Hong Kong, Med Data Analyt Ctr, Dept Med & Therapeut, Hong Kong, Peoples R China
[5] Chinese Univ Hong Kong, Inst Digest Dis, State Key Lab Digest Dis, Hong Kong, Peoples R China
[6] Univ Calif San Diego, Div Gastroenterol & Hepatol, La Jolla, CA 92093 USA
关键词
CIRRHOSIS; HEPATITIS;
D O I
10.1111/apt.17846
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
BackgroundThe American and European liver associations have endorsed new nomenclature of steatotic liver disease (SLD) and definition of metabolic dysfunction-associated steatotic liver disease (MASLD).AimsTo review the historical development leading to the changes and to discuss the implications of the changes on research and clinical practiceMethodsWe performed a literature search using keywords related to MASLD and non-alcoholic fatty liver disease (NAFLD).ResultsThe SLD umbrella allows classification of patients under the key categories of MASLD, alcohol-associated liver disease and a new entity termed MetALD, which represents MASLD with increased alcohol intake. The diagnosis of MASLD requires the demonstration of hepatic steatosis and at least one metabolic risk factor, whereas MASLD can co-exist with other liver diseases such as chronic viral hepatitis. Despite the change in definition, over 95% of patients previously known as having NAFLD fulfil diagnostic criteria for MASLD. It is conceivable that future clinical trials and biomarker studies will continue to exclude concomitant liver diseases. As most patients with MASLD are seen at primary care and non-hepatology settings, communication with other stakeholders is essential to ensure disease awareness and smooth adoption of the changes.ConclusionsThe new nomenclature is both a challenge, given the need for dissemination and education across the spectrum of stakeholders, and an opportunity to bring everyone together and spark new research to better understand epidemiology, natural history, diagnosis, biomarkers and management strategies across the spectrum of SLD. The American and European liver associations have endorsed new nomenclature of steatotic liver disease and definition of metabolic dysfunction-associated steatotic liver disease. The definition recognises the spectrum of disease due to metabolic risk factors, alcohol consumption, or both. This review article discusses the historical development leading to the changes and the implications of the changes on research and clinical practice.image
引用
收藏
页码:150 / 156
页数:7
相关论文
共 50 条
  • [1] Metabolic dysfunction-associated steatotic liver disease and the heart
    Driessen, Stan
    Francque, Sven M.
    Anker, Stefan D.
    Cabezas, Manuel Castro
    Grobbee, Diederick E.
    Tushuizen, Maarten E.
    Holleboom, Adriaan G.
    [J]. HEPATOLOGY, 2023,
  • [2] Menopause and metabolic dysfunction-associated steatotic liver disease
    Polyzos, Stergios A.
    Goulis, Dimitrios G.
    [J]. MATURITAS, 2024, 186
  • [3] Metabolic dysfunction-associated steatotic liver disease and atherosclerosis
    Castillo-Nunez, Yulino
    Almeda-Valdes, Paloma
    Gonzalez-Galvez, Guillermo
    Arechavaleta-Granell, Maria del Rosario
    [J]. CURRENT DIABETES REPORTS, 2024, 24 (07) : 158 - 166
  • [4] Nutrients associated with metabolic dysfunction-associated steatotic liver disease
    Jeong, Seogsong
    [J]. JOURNAL OF HEPATOLOGY, 2024, 80 (02) : e81 - e82
  • [5] Metabolic dysfunction-associated steatotic liver disease and risk of cardiovascular disease
    Lee, Hyeok-Hee
    Lee, Han Ah
    Kim, Eun-Jin
    Kim, Hwi Young
    Kim, Hyeon Chang
    Ahn, Sang Hoon
    Lee, Hokyou
    Kim, Seung Up
    [J]. GUT, 2024, 73 (03) : 533 - 540
  • [6] New Nomenclature for Nonalcoholic Fatty Liver Disease: Understanding Metabolic Dysfunction-Associated Steatotic Liver Disease, Metabolic Dysfunction- and Alcohol-Associated Liver Disease, and Their Implications in Clinical Practice
    Canivet, Clemence M.
    Boursier, Jerome
    Loomba, Rohit
    [J]. SEMINARS IN LIVER DISEASE, 2024, 44 (01) : 35 - 42
  • [7] Monitoring disease progression in metabolic dysfunction-associated steatotic liver disease
    Noureddin, Nabil
    Copur-Dahi, Nedret
    Loomba, Rohit
    [J]. ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2024, 59 : S41 - S51
  • [8] Elucidating cuproptosis in metabolic dysfunction-associated steatotic liver disease
    Li, Yamei
    Qi, Ping
    Song, Si -Yuan
    Wang, Yiping
    Wang, Hailian
    Cao, Peng
    Liu, Yu 'e
    Wang, Yi
    [J]. BIOMEDICINE & PHARMACOTHERAPY, 2024, 174
  • [9] Metabolic dysfunction-associated steatotic liver disease: A silent pandemic
    Samanta, Arghya
    Sen Sarma, Moinak
    [J]. WORLD JOURNAL OF HEPATOLOGY, 2024, 16 (04)
  • [10] Phytonanotherapy for the Treatment of Metabolic Dysfunction-Associated Steatotic Liver Disease
    Nendouvhada, Livhuwani P.
    Sibuyi, Nicole R. S.
    Fadaka, Adewale O.
    Meyer, Samantha
    Madiehe, Abram M.
    Meyer, Mervin
    Gabuza, Kwazikwakhe B.
    [J]. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2024, 25 (11)